Page last updated: 2024-08-22

samarium and ER-Negative PR-Negative HER2-Negative Breast Cancer

samarium has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
An, P; Chen, F; Chen, J; Gao, Z; Li, Y; Sun, B; Wang, Z; You, C; Zhang, Y	1

Other Studies

1 other study(ies) available for samarium and ER-Negative PR-Negative HER2-Negative Breast Cancer

Article	Year
A CD44-targeted Cu(ii) delivery 2D nanoplatform for sensitized disulfiram chemotherapy to triple-negative breast cancer. Nanoscale, 2020, Apr-21, Volume: 12, Issue:15 Topics: Animals; Cell Line, Tumor; Copper; Disulfiram; Drug Carriers; Drug Delivery Systems; Female; Humans; Hyaluronan Receptors; Hyaluronic Acid; Mice; Nanostructures; Porphyrins; Samarium; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays	2020

Article

Year

A CD44-targeted Cu(ii) delivery 2D nanoplatform for sensitized disulfiram chemotherapy to triple-negative breast cancer.

Nanoscale, 2020, Apr-21, Volume: 12, Issue:15

Topics: Animals; Cell Line, Tumor; Copper; Disulfiram; Drug Carriers; Drug Delivery Systems; Female; Humans; Hyaluronan Receptors; Hyaluronic Acid; Mice; Nanostructures; Porphyrins; Samarium; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2020